Oncolytics Biotech ONCY's latest lobbying report covers Q2 2026, at $105K. Its first report covers Q1 2026; the issues it reports most are Health Issues.

Oncolytics BiotechONCY

Oncolytics Biotech stock page

Latest quarter: No record; Q3 2026 · 0 reports
Last 12 months: $140K; Last 3 quarters
vs last quarter: −100.0%; Q3 2026 against the quarter before
First report: Q1 2026; The first quarter a report named it

Lobbying by quarter

By issue

Health issues$140K · 2 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

HOUSE OF REPRESENTATIVES2 reports
SENATE2 reports

Firms it paid

Firm
TSG Advocates DC	$140K	2 quarters

Former officials lobbying for it

	Former position	Firm
NICK RAINERI	Rep. Jim Banks, Director of Member Services Main Street Caucus, Executive Director Rep. Dan Meuser, Chief of Staff Rep. Byron Donalds, Senior Advisor Department of Defense, Office of Strategic Capital, Senior Advisor	TSG Advocates DC	Q2 2026

Lobbying reports

	Filed by		Issues
07/20for Q2	TSG Advocates DC	$105K	Health issues
05/08for Q1	TSG Advocates DC	$35K	Health issues
05/04for Q1	TSG Advocates DC	Under $5,000	Health issues